This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for June 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Will Altria (MO) Stock Recover on RRPs and Shareholder Moves?
by Zacks Equity Research
Altria (MO) consistently focuses on strengthening RRPs category to offset declining cigarette volumes. Its shareholder friendly moves bode well.
Is Phillip Morris' Weak Volumes a Concern for Tobacco Firms?
by vidya Nair
Weak shipment volumes stemming from declining cigarette sales have long been a hurdle for firms in the tobacco space. However, RRPs are likely to continue expanding.
Zacks Investment Ideas feature highlights: Phillip Morris International, Altria and British American Tobacco
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Phillip Morris International, Altria and British American Tobacco
Can Smokeless Unit Aid Altria (MO) This Earnings Season?
by Zacks Equity Research
Altria's (MO) first-quarter 2018 results are likely to benefit from RRPs. However, dismal cigarette volumes are a concern.
Are Cigarettes Finally Dead? Phillip Morris Plunges
by David Borun
Despite beating estimates for net Q1 earnings, the international tobacco giant plunges, taking industry peers with
Philip Morris (PM) Q1 Earnings: Can RRPs Pare Cigarette Woe?
by Zacks Equity Research
Although Philip Morris (PM) continues to struggle with lower cigarette consumption, its first-quarter 2018 results are likely to gain from steady advancements in reduced risk products.
How MO & 3 Others Are Placed in a Challenging Tobacco Space
by vidya Nair
While stringent FDA regulations mar cigarette sales, tobacco firms are trying to stay afloat with RRPs.
What Philip Morris' Plant Conversion Could Mean for the Stock
by Zacks Equity Research
Philip Morris (PM) continues to enhance its RRPs category. The company announces plans to convert one of its cigarette production facilities in Greece for manufacturing smoke-free tobacco units.
Altria Loses 15% in a Year: Can Strategic Efforts Aid Growth?
by Zacks Equity Research
Amid numerous headwinds plaguing cigarette consumption, Altria (MO) manages to stay afloat in the industry on the back of smokeless products and strong pricing strategies.
Will Philip Morris' Efforts to Expand RRPs Fuel Growth?
by Zacks Equity Research
Philip Morris (PM) strives to expand in the reduced risk products category as cigarette volumes continue to decline globally.
Smokeless Unit & Pricing to Fuel Altria (MO) in Q4 Earnings?
by Zacks Equity Research
In 4Q17, we expect Altria (MO) to gain from strong pricing and focus on smokeless unit, though softness in its smokeable and wine segments remain concerns.
Can Philip Morris' (PM) RRPs Help It Tide Over Hurdles?
by Zacks Equity Research
Philip Morris (PM) continues to benefit from reduced risk products expansion efforts. However, declining cigarette consumption is a woe.
Can Altria's (MO) Focus on Smokeless Products Fuel Growth?
by Zacks Equity Research
Declining demand for tobacco products and stringent government regulations have been weighing upon Altria (MO). However, management has been actively working toward producing smokeless products.
Can Smokeless Unit Help Altria (MO) Make a Comeback in 2018?
by Zacks Equity Research
Although Altria (MO) has been grappling with issues stemming from stern regulations, the growing popularity of smokeless products up lifts hopes for the company's revival.
Will Philip Morris' Cigarette Category Continue to Struggle?
by Zacks Equity Research
Philip Morris (PM) has been struggling with lower cigarette sales volumes due to stringent government regulations surrounding tobacco consumption.
Can Altria's Efforts Offer Respite From Weak Smokeable Unit?
by Zacks Equity Research
Altria (MO) strengthens smokeless category amid industry-wide headwinds and declining tobacco consumption.
Can Philip Morris' Low Risk Products Counter Industry Woes?
by Zacks Equity Research
Phillip Morris (PM) invests in reduce risk products to counter low cigarette consumption.
Smokeless Products' Strength to Drive Altria (MO) Q3 Earnings
by Zacks Equity Research
Altria's (MO) third-quarter 2017 results are likely to gain from revenue growth in the smokeless category. However, declining volumes have been limiting growth for smokeable products.
Philip Morris (PM) Q3 Earnings to Gain From iQOS Products
by Zacks Equity Research
Declining cigarette sales volumes expected to hurt Philip Morris' (PM) third-quarter results. However, the company expects significant growth in its heated tobacco products.
What Impact Will Self-Critical Ads Have on Tobacco Stocks?
by Zacks Equity Research
Increasing FDA regulation has dented tobacco companies' revenues significantly. The latest move to advertise against cigarettes is expected to raise concerns of accelerated sales declines for traditional cigarettes.
6 Reasons to Hold Philip Morris (PM) Despite Industry Woes
by Zacks Equity Research
Tobacco stocks are facing declining cigarette volumes amid increasing government restrictions and declining smoking rates. Nevertheless, Philip Morris can prove to be a boon for investors.
Here's Why You Should Hold on to Altria (MO) Stock Right Now
by Zacks Equity Research
Amid declining tobacco sales volumes and government restrictions, Altria (MO) has been benefiting from low-risk smokeless tobacco products.
4 High-Dividend Tobacco Picks to Add Value to Your Portfolio
by Zacks Equity Research
Tobacco stocks are facing declining cigarette volumes amid increasing government restrictions and declining smoking rates. Nevertheless, these stocks can prove to be a boon for investors.
Tobacco Stocks Fall After FDA Targets Nicotine in Cigarette
by Zacks Equity Research
The news of cutting nicotine to non-addictive or minimally addictive levels have raised concerns of accelerated sales declines for traditional cigarettes, while demand for e-cigarettes is on the rise.